Vita Life SciencesASX:VLS -2.00%85 PS Ratio is 1.49 as of Jun. 27, 2026, which is 7% above its 10-year median of 1.39. GuruFocus rates ASX:VLS with a GF Score™ of 85/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 953 Drug Manufacturers companies, Vita Life Sciences ranks better than 63.9% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vita Life Sciences's share price is A$2.45.
Vita Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.64. Hence, Vita Life Sciences's PS Ratio for today is 1.49.
Good Sign:
Vita Life Sciences Ltd stock PS Ratio (=1.52) is close to 1-year low of 1.38.
The historical rank and industry rank for Vita Life Sciences's PS Ratio or its related term are showing as below:
ASX:VLS'
s PS Ratio Range Over the Past 10 Years
Min: 0.7 Med: 1.39 Max: 2.42
Current: 1.49
During the past 13 years, Vita Life Sciences's highest PS Ratio was 2.42. The lowest was 0.70. And the median was 1.39.
ASX:VLS's PS Ratio is ranked better than 63.9% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.2
vs ASX:VLS: 1.49
Vita Life Sciences Ltd has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of Vita Life Sciences was 14.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.40% per year.
During the past 13 years, Vita Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 19.10% per year. The lowest was -6.20% per year. And the median was 9.90% per year.
Back to Basics: PS Ratio
Vita Life Sciences (ASX:VLS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Vita Life Sciences PS Ratio Related Terms
Vita Life Sciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Vita Life Sciences's Share Price of today is A$2.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vita Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Vita Life Sciences (ASX:VLS) has a PS Ratio of 1.49 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 1.39. Over the past decade, Vita Life Sciences' PS Ratio has ranged from 0.70 to 2.42. According to the industry distribution chart, Vita Life Sciences ranks #344 out of 953 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is Vita Life Sciences' PS Ratio too high?
Vita Life Sciences' current PS Ratio of 1.49 is near median its 10-year median of 1.39. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 2.42. The Drug Manufacturers industry median PS Ratio is 2.20. Vita Life Sciences' value of 1.49 is 32.3% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #344 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #344 out of 953 companies for PS Ratio. This puts Vita Life Sciences in the upper half of its industry. The industry median PS Ratio is 2.20. Vita Life Sciences' value of 1.49 is 32.3% below this benchmark. Historically, Vita Life Sciences' own PS Ratio has ranged from 0.70 to 2.42 over the past decade. While the company's 10-year median is 1.39 vs. the industry median of 2.20, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current PS Ratio of 1.49 is 32.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current PS Ratio is 1.49, which is near median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.45 — trading 1.2% below its estimated fair value. The current PS Ratio is 1.49, which is near median its 10-year median of 1.39 and 32.3% below the Drug Manufacturers industry median of 2.20. Vita Life Sciences' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current PS Ratio is 1.49 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.45 is trading 1.2% below its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
PS Ratio: 1.49 (near median its 10-year median of 1.39)
GF Value™: A$2.48 vs. price of A$2.45 (1.2% below fair value)
Industry Position: 32.3% below the Drug Manufacturers median (#344 of 953)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
85GF Score
Get the complete analysis for ASX:VLS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
